Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin

Post time 3 day(s) ago

journal：Endocrine Practice

Authors：Xi Chen; Yongping Xu; Jianhua Zhang; Shiyin Shao; Yanran Duan; Peiwen Liu; Liya Shen; Jing Zhang; Jiaoe Zeng; Mei Lin; Shi Zhao; Jianhua Ma; Tao Zhao; Juping Hu; Yong Liao; Xiaowen Chen; Shufang Hu; Yaoming Xue; Zhaoyang Zeng; Wentao He; Zhelong Liu; Wenjun Li; Liegang Liu; Ping Yin; Xuefeng Yu

Published date：2021-8-

DOI：10.1016/j.eprac.2021.03.015

PDF link：https://www.sciencedirect.com/sc ... 530891X21001221/pdf

Article link：https://doi.org/10.1016/j.eprac.2021.03.015

Article Source：Elsevier BV。

Remark：

Post time 3 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin